EM Imaging obtains license for fluorescence imaging agent that detects bowel cancer early

Sept. 23, 2015
EM Imaging has signed an exclusive agreement for a novel fluorescence imaging agent that could improve bowel cancer detection.

Edinburgh Molecular Imaging (EM Imaging; Edinburgh, Scotland) has signed an exclusive global license for a novel fluorescence imaging agent that could improve the detection of early-stage colorectal (bowel) cancer.

Related: 'Painting' tumors to guide cancer surgery

The company signed the licensing agreement with medical imaging systems maker GE Healthcare (Wilmington, MA). Now, EM Imaging will complete development of the EMI-137 imaging agent that can help doctors identify bowel cancer early.

EMI-137 is a water-soluble compound consisting of a 26–amino acid cyclic peptide, conjugated to a fluorescent cyanine dye, that binds to human tyrosine kinase c-Met, a receptor frequently overexpressed during cancer growth. EMI-137 has the potential on intravenous administration to image a wide range of cancers, including breast cancer, esophageal cancer, ovarian cancer, thyroid cancer, bile duct carcinoma, and lung cancer, because it specifically targets the c-Met receptor.

In a recent study, the EMI-137 agent allowed doctors to see more early-stage colorectal cancer (CRC) and precancerous tumors, which can then easily be removed via colonoscopy. However, screening with a colonoscope, which is currently the most common method, can miss up to 25% of precancerous growths, especially smaller, flat lesions. Dr. James Hardwick, the lead investigator on the study, said that they detected 47 precancerous polyps in the study, but 12 were missed using a standard colonoscope.

Fluorescence colonoscopy in patients receiving intravenous EMI-137 enabled visualization of all neoplastic polyps that were visible with white light, and detected previously missed polyps that were not visible with white light alone. This enables the detection of polyps missed by other techniques.

Ian Wilson, CEO of EM Imaging, says that the company will continue to explore EMI-137's utility in visualizing tumors during surgery, with additional studies planned to begin before the end of 2015.

Full details of the recent study appear in the journal Nature Medicine; for more information, please visit http://dx.doi.org/10.1038/nm.3641.

Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)

Sponsored Recommendations

How Precision Motion Systems are Shaping the Future of Semiconductor Manufacturing

March 28, 2024
This article highlights the pivotal role precision motion systems play in supporting the latest semiconductor manufacturing trends.

Understanding 3D Printing Tolerances: A Guide to Achieving Precision in Additive Manufacturing

March 28, 2024
In the world of additive manufacturing, precision is paramount. One crucial aspect of ensuring precision in 3D printing is understanding tolerances. In this article, we’ll explore...

Automation Technologies to Scale PIC Testing from Lab to Fab

March 28, 2024
This webinar will cover the basics of precision motion systems for PIC testing and discuss the ways motion solutions can be specifically designed to address the production-scale...

Case Study: Medical Tube Laser Processing

March 28, 2024
To enhance their cardiovascular stent’s precision, optimize throughput and elevate part quality, a renowned manufacturer of medical products embarked on a mission to fabricate...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!